ArticleFrontiers in oncology2026
Clinical spectrum and treatment of thyroid lymphoma: results of a cohort study of 61 patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid lymphoma (TL) is a rare malignancy. Its diagnosis is challenging due to non-specific clinical features, with management controversies, concurrent with Hashimoto's thyroiditis (HT), and heterogeneous prognoses across subtypes. This study aimed to analyze clinical spectrum and explore optimal treatment strategies to improve prognosis of TL. Methods: A retrospective cohort study was conducted on 61 patients with TL diagnosed in the First Affiliated Hospital of Zhengzhou University from 2014 to 2025. Results: Among 61 patients, 67.2% had concurrent HT. The TL+ group (TL with extrathyroid involvement, 11 patients, 18.0%) showed more frequent subdiaphragmatic lymph node involvement (p<0.001) and perivascular lymph node involvement (p=0.003) compared with the iTL group (isolated TL, 50 patients, 82.0%). With a median follow-up of 22 months, the 1-, 3-, and 5-year OS rates were 85.0%, 78.4%, and 75.6%, and PFS rates were 76.5%, 71.7%, and 63.1%. DLBCL was the most common histological subtype, accounting for 60.7% of all TL cases. In patients with thyroid diffuse large B-cell lymphoma (TDLBCL), age ≥60 years and C-myc expression ≥50% were independent risk factors for shorter PFS, whereas chemotherapy was independently associated with improved PFS and OS. Surgery alone without chemotherapy was associated with shorter PFS in univariate analysis. Conclusions: TL with extrathyroidal involvement shares features with isolated disease but requires Ann Arbor staging-guided management. Chemotherapy was independently associated with improved PFS and OS in patients with thyroid diffuse large B-cell lymphoma, whereas older age and high C-myc expression were independently associated with inferior PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.